ES2684173T3 - Anticuerpos anti-XCR1 humano - Google Patents
Anticuerpos anti-XCR1 humano Download PDFInfo
- Publication number
- ES2684173T3 ES2684173T3 ES12761822T ES12761822T ES2684173T3 ES 2684173 T3 ES2684173 T3 ES 2684173T3 ES 12761822 T ES12761822 T ES 12761822T ES 12761822 T ES12761822 T ES 12761822T ES 2684173 T3 ES2684173 T3 ES 2684173T3
- Authority
- ES
- Spain
- Prior art keywords
- cdr
- seq
- amino acid
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 18
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 abstract 1
- 102000045922 human XCR1 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530194P | 2011-09-01 | 2011-09-01 | |
| US201261659637P | 2012-06-14 | 2012-06-14 | |
| PCT/JP2012/072667 WO2013032032A1 (en) | 2011-09-01 | 2012-08-30 | Anti-human xcr1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2684173T3 true ES2684173T3 (es) | 2018-10-01 |
Family
ID=46881120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12761822T Active ES2684173T3 (es) | 2011-09-01 | 2012-08-30 | Anticuerpos anti-XCR1 humano |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9371389B2 (enExample) |
| EP (1) | EP2751140B1 (enExample) |
| JP (1) | JP5989096B2 (enExample) |
| KR (1) | KR101767717B1 (enExample) |
| CN (1) | CN103764680B (enExample) |
| AR (1) | AR087749A1 (enExample) |
| AU (1) | AU2012302596B2 (enExample) |
| BR (1) | BR112014004352A2 (enExample) |
| CA (1) | CA2846370C (enExample) |
| ES (1) | ES2684173T3 (enExample) |
| HK (1) | HK1199038A1 (enExample) |
| IL (1) | IL231075A (enExample) |
| IN (1) | IN2014CN01466A (enExample) |
| MX (1) | MX346560B (enExample) |
| MY (1) | MY166152A (enExample) |
| PH (1) | PH12014500384A1 (enExample) |
| RU (1) | RU2619180C2 (enExample) |
| TW (1) | TWI563004B (enExample) |
| WO (1) | WO2013032032A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6208864B2 (ja) * | 2013-06-24 | 2017-10-04 | エービーエルバイオ | 安定性が改善された抗体−薬物結合体およびこれの用途 |
| SMT202200317T1 (it) * | 2015-08-05 | 2022-09-14 | Inst Nat Sante Rech Med | Anticorpi anti-gpvi umana innovativi e relativi usi |
| US11692033B2 (en) | 2017-02-03 | 2023-07-04 | Acticor Biotech | Inhibition of platelet aggregation using anti-human GPVI antibodies |
| EP3580230A1 (en) | 2017-02-07 | 2019-12-18 | VIB vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| CN107312092B (zh) * | 2017-05-04 | 2020-12-11 | 华南农业大学 | 一种斜带石斑鱼ccr12的多克隆抗体制备方法及其应用 |
| US20210130776A1 (en) * | 2017-09-29 | 2021-05-06 | The Broad Institute, Inc. | Methods and compositions for modulating suppression of lymphocyte activity |
| WO2019148089A1 (en) | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| JP7677892B2 (ja) | 2018-12-28 | 2025-05-15 | エフ． ホフマン－ラ ロシュ アーゲー | 免疫応答が増幅された患者における治療的使用のためのペプチド－ｍｈｃ－ｉ－抗体融合タンパク質 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5786210A (en) | 1994-02-08 | 1998-07-28 | Schering Corporation | Mammalian thymokine genes |
| AU2001250412A1 (en) * | 2000-03-31 | 2001-10-08 | Ipf Pharmaceuticals Gmbh | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| AU2002246557A1 (en) * | 2000-11-29 | 2002-08-06 | Lifespan Biosciences, Inc. | Compositions and methods related to chemokine (c motif) xc receptor 1 (ccxcr1) |
| US20050136033A9 (en) | 2002-08-13 | 2005-06-23 | Matthias Mack | Method of treating allergen induced airway disease |
| WO2004072646A1 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5) |
| EP1698902A1 (en) * | 2005-03-01 | 2006-09-06 | DKFZ Deutsches Krebsforschungszentrum | Use of XCR1 for diagnosing or monitoring of immune tolerance |
| CN101293924A (zh) * | 2007-04-24 | 2008-10-29 | 上海国健生物技术研究院 | 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途 |
| EP2062592A1 (en) * | 2007-11-20 | 2009-05-27 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | System for delivery into a XCR1 positive cell and uses thereof |
| CN102439163A (zh) * | 2009-02-16 | 2012-05-02 | 拜奥雷克斯治疗公司 | 人源化抗cd20抗体及使用方法 |
-
2012
- 2012-08-30 KR KR1020147004507A patent/KR101767717B1/ko not_active Expired - Fee Related
- 2012-08-30 BR BR112014004352A patent/BR112014004352A2/pt not_active Application Discontinuation
- 2012-08-30 EP EP12761822.1A patent/EP2751140B1/en not_active Not-in-force
- 2012-08-30 ES ES12761822T patent/ES2684173T3/es active Active
- 2012-08-30 PH PH1/2014/500384A patent/PH12014500384A1/en unknown
- 2012-08-30 WO PCT/JP2012/072667 patent/WO2013032032A1/en not_active Ceased
- 2012-08-30 AU AU2012302596A patent/AU2012302596B2/en not_active Ceased
- 2012-08-30 IN IN1466CHN2014 patent/IN2014CN01466A/en unknown
- 2012-08-30 CA CA2846370A patent/CA2846370C/en not_active Expired - Fee Related
- 2012-08-30 MX MX2014002078A patent/MX346560B/es active IP Right Grant
- 2012-08-30 RU RU2014106832A patent/RU2619180C2/ru not_active IP Right Cessation
- 2012-08-30 CN CN201280041366.2A patent/CN103764680B/zh not_active Expired - Fee Related
- 2012-08-30 US US14/240,090 patent/US9371389B2/en not_active Expired - Fee Related
- 2012-08-30 AR ARP120103217A patent/AR087749A1/es unknown
- 2012-08-30 TW TW101131633A patent/TWI563004B/zh not_active IP Right Cessation
- 2012-08-30 MY MYPI2014700412A patent/MY166152A/en unknown
- 2012-08-30 JP JP2014509528A patent/JP5989096B2/ja not_active Expired - Fee Related
- 2012-08-30 HK HK14112359.4A patent/HK1199038A1/xx unknown
-
2014
- 2014-02-20 IL IL231075A patent/IL231075A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014527396A (ja) | 2014-10-16 |
| RU2619180C2 (ru) | 2017-05-12 |
| TW201311725A (zh) | 2013-03-16 |
| CA2846370C (en) | 2019-04-23 |
| TWI563004B (en) | 2016-12-21 |
| HK1199038A1 (en) | 2015-06-19 |
| AU2012302596B2 (en) | 2016-12-01 |
| MX346560B (es) | 2017-03-24 |
| CA2846370A1 (en) | 2013-03-07 |
| MX2014002078A (es) | 2014-05-30 |
| IN2014CN01466A (enExample) | 2015-05-08 |
| AR087749A1 (es) | 2014-04-16 |
| IL231075A0 (en) | 2014-03-31 |
| PH12014500384A1 (en) | 2014-04-14 |
| CN103764680A (zh) | 2014-04-30 |
| BR112014004352A2 (pt) | 2017-03-21 |
| AU2012302596A1 (en) | 2014-03-06 |
| CN103764680B (zh) | 2016-11-23 |
| EP2751140B1 (en) | 2018-05-30 |
| RU2014106832A (ru) | 2015-08-27 |
| MY166152A (en) | 2018-06-06 |
| EP2751140A1 (en) | 2014-07-09 |
| US20140193421A1 (en) | 2014-07-10 |
| US9371389B2 (en) | 2016-06-21 |
| IL231075A (en) | 2017-08-31 |
| JP5989096B2 (ja) | 2016-09-07 |
| KR20140054108A (ko) | 2014-05-08 |
| WO2013032032A1 (en) | 2013-03-07 |
| NZ621320A (en) | 2015-11-27 |
| KR101767717B1 (ko) | 2017-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2684173T3 (es) | Anticuerpos anti-XCR1 humano | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| PE20121361A1 (es) | Antagonistas de pcsk9 | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| MX2018003410A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| RU2017129721A (ru) | АНТИТЕЛА ПРОТИВ αβTCR | |
| ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 | |
| ES2620264T3 (es) | Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА |